MedTrace Logo

Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

NCT06664528 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-03-04

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.

The main purposes of the study are the following:

* Identify the demographic factors related to the onset of cardiotoxicity produced by anticancer drugs.
* Identify any subgroups more likely to develop distant major adverse cardiovascular events (MACE).
* Evaluate the usefulness of clinical, biohumoral and echocardiographic parameters for early diagnosis of cardiotoxicity.

Participants will be monitored during the anticancer treatment via clinical, laboratory and instrumental evaluation according to the recommendation of the current guidelines on Cardio-Oncology (European Society of Cardiology, 2022). Initial follow-up will be 2 years.

Conditions

Interventions

DIAGNOSTIC_TEST

LABORATORY TESTS

The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.

DIAGNOSTIC_TEST

ECHOCARDIOGRAPHY

A complete echocardiographic exam will be performed during each cardio-oncologic evaluation.

DIAGNOSTIC_TEST

ELECTROCARDIOGRAPHY (ECG)

An ECG tracing will be obtained during each cardio-oncologic evaluation.

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Principal Investigators

  • Antonella Lombardo · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2028-11-15
Completion
2028-12-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06664528 on ClinicalTrials.gov